# Nimotuzumab Plus S1 Versus Placebo Plus S1 as Maintenance Treatment in Patients With Unresectable Pancreatic Cancer

> **NCT02945267** · PHASE4 · UNKNOWN · sponsor: **Chinese PLA General Hospital** · enrollment: 60 (estimated)

## Conditions studied

- Unresectable Pancreatic Cancer

## Interventions

- **DRUG:** Nimotuzumab plus S1
- **DRUG:** Placebo plus S1

## Key facts

- **NCT ID:** NCT02945267
- **Lead sponsor:** Chinese PLA General Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2016-09
- **Primary completion:** 2018-12
- **Final completion:** 2019-12
- **Target enrollment:** 60 (ESTIMATED)
- **Last updated:** 2016-10-26


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02945267

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02945267, "Nimotuzumab Plus S1 Versus Placebo Plus S1 as Maintenance Treatment in Patients With Unresectable Pancreatic Cancer". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT02945267. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*